TRVN 2.19 0.04 (1.79%). The other top investors are Blackrock Inc. which holds 2.35 million shares representing 1.49% and valued at over $7.02 million, while Geode Capital Management, LLC holds 0.66% of the shares totaling 1.04 million with a market value of $3.1 million. About the Trevena, Inc. stock forecast. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. 4 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders. Currently trading at $2.14, the stock is -5.81% and -11.81% below its SMA20 and SMA50 respectively. According to 4 analysts, the average rating for Trevena stock is "Buy." Trevena sees a significant clinical need in the hospital setting for an effective and well-tolerated IV analgesic to help manage patients’ moderate-to-severe pain. Exploring Trevena (NASDAQ:TRVN) stock? Short interest in the company’s stock has fallen -2.96% from the last report on Nov 12, 2020 to stand at a total of 23.66 million short shares sold with a short interest ratio of 7.17. Trevena Inc. (NASDAQ: TRVN) is 154.49% higher on its value in year-to-date trading and has touched a low of $0.46 and a high of $3.68 in the current 52-week trading range. Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public âcrypto stocksâ are surging right along with them. Trevena Inc stock is up 82.29% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives TRVN stock a score of 94 out of a possible 100.. That rank is influenced by a long-term technical score of 99. spam. 4 of the analysts rate the stock as a “Buy”. 72 institutions hold shares in Trevena Inc. (TRVN), with 2.48M shares held by insiders accounting for 1.58% while institutional investors hold 11.84% of the company’s shares. Price target in 14 days: 2.632 USD. Distance from 52-week low is 365.22% and -41.85% from its 52-week high. The 12-month stock price forecast is 5.25, which is an increase of 145.33% from the latest price. Not many small-cap bios can boast that and Trevena certainly can. To add more color to this target, the company’s high over the last year is $2.39 and the low is $0.46. Last month, Trevena raised $50 million. It is also 64.33% off the consensus price target high of $6.00 offered by 4 analysts, but current levels are 57.2% higher than the price target low of $5.00 for the same period. The 2021 Backdoor Crypto Portfolio (free). We are not receiving compensation for it. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. No Hidden Fees. Enterprise Associates 12 Limited Partnership New is the largest individual Trevena shareholder, owning 4.81M shares representing 3.66% of the company. Even if youâre not actively in crypto, you deserve to know whatâs actually going on... wrote this article ourselves and it expresses our own opinions. Itâs free. Trevena Inc. is expected to release its quarterly report on 05/06/2021 and quarterly earnings per share for the current quarter are estimated at -$0.07.The EPS is expected to grow by 35.20% this year, but quarterly earnings will post 9,577.40% year-over-year. Click here to get the full story⦠along with our long list of backdoor Bitcoin strategies. The investor’s holdings represent 4.31% of the TRVN Shares outstanding. It can be used to make informed decisions about market timing, and when buying or selling Trevena shares will generate the highest return on investment. At current levels, Trevena is a discount entry opportunity and one with limited downside, especially now that it has an FDA-approved drug. Trevena, Inc., which has a market valuation of $359.14 Million, is expected to release its quarterly earnings report Mar 10, 2021- Mar 15, 2021. The recent excitement surrounding Trevena pertains to Olivynk. Trevena Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Analyst projections state that TRVN is forecast to be at a low of $5 and a high of $6. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. Join now to get the NewsHeater.com pre-market morning brief 100% free. 's earnings in 2021 is -$23,943,000.. On average, 2 Wall Street analysts forecast TRVN's earnings for 2021 to be $-38,830,982, with the lowest TRVN earnings forecast at $-42,121,743, and the highest TRVN earnings forecast at $-35,540,221. 0 analysts have rated the stock as a Sell or Underperform. This article is not a solicitation or recommendation to buy, sell, or hold securities. Q BioMed Inc (OTCMKTS:QBIO) A Bounce Back Play On Opioid Crisis Opportunity, Elite Pharmaceuticals Inc (OTCMKTS:ELTP) Takes a Giant Leap in its Pursuit of Remedies, Biocorrx Inc (OTCMKTS:BICX) Is An Opioid Crisis Play, Using OTC Techniques to Buy and Sell Blue Chip Stocks. Trevena Inc. analyst estimates, including TRVN earnings per share estimates and analyst recommendations. AcelRx Pharmaceuticals Inc. (ACRX) is -40.10% down on the 1-year trading charts. Trevena. On average, analysts expect that Trevena will report full year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.22) to ($0.21). Trevena Stock Forecast, TRVN stock price prediction. This article is meant for informational and educational purposes only and does not provide investment advice. Get the latest Trevena detailed stock quotes, stock trade data, stock price info, and performance analysis, including Trevena … Insider Financial is not an investment advisor and does not provide investment advice. Trevena Inc Stock Price Forecast, "TRVN" Predictons for2021 Always do your own research and make your own investment decisions. For the past year, shares of Trevena (NASDAQ:TRVN) haven’t really done much. The company’s main competitors (and peers) include Arena Pharmaceuticals Inc. (ARNA) that is trading 66.15% up over the past 12 months. Our stock price predictions cover a period of 3 months. We are a little more bullish. Analyst recommendations provided by FactSet shows that the consensus forecast for Trevena Inc. (TRVN) is a “Buy”. Small-cap biotechs usually trade at 5x sales. This is a 2.19% increase since the beginning of the trading day. Cantor Fitzgerald just came out and issued a $5 price target in its recent Trevena stock forecast. TRVN's rank also includes a short-term technical score of 94. Aethlon Medical Inc. (AEMD) Review – Making Smarter Decisions, SPAR Group Inc. (SGRP) picks momentum as shares rise 12.75%, Here is a breakdown of major shareholders in Spotify Technology S.A. (NYSE: SPOT), Hologic Inc. (HOLX) Review – Making Smarter Decisions, Which institution holds the most shares in Assembly Biosciences Inc. (ASMB), ImmunoGen (IMGN) Burning their Cash for Positive Outcomes, What to expect from Proto Labs Inc.’s (PRLB) Earnings. Trevena NASDAQ Updated Feb 24, 2021 12:00 AM. As always, good luck to all (except the shorts)! View Trevena's (NASDAQ:TRVN) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. As things progress with Olinvyk as it gets into more hospitals and becomes the go-to treatment for pain, we expect its market cap to reflect its true potential. If you have an interest in the lucrative microcap sector, sign up to Insider Financial today! Analyst recommendations provided by FactSet shows that the consensus forecast for Trevena Inc. (TRVN) is a “Buy”. Previously, H.C. Wainwright analyst Douglas Tsao also raised his price target to $5 on the Olinvyk news. This article is meant for informational and educational purposes only and does not provide investment advice. We are a little more bullish. We will continue to do everything we can to reduce the number of Americans who are addicted to opioids and cut the rate of new addiction through a number of cross-agency initiatives,” said Douglas Throckmorton M.D., deputy director for regulatory programs in the FDA’s Center for Drug Evaluation and Research. Stock analysis is the technique used by a trader or investor to examine and evaluate how Trevena stock is reacting to, or reflecting on a current stock market direction and economic conditions. We have no business relationship with any company whose stock is mentioned in this article. Trevena is selling for 2.33 as of the 20th of February 2021. The Trevena stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. In order for the stock price to hit the forecast high, the stock would need to surge +154.24% from its current level, while the stock would need to crash 111.86% from its current level to reach the projected low. The FDA said in granting approval: “Addressing the opioid crisis remains a top priority for the FDA. “Importantly, the FDA will only approve new drug applications, including those for opioid medications, following a rigorous review to evaluate the risks and benefits and ultimate determination that the data support safety and effectiveness. Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. Post-Market 0.03 (1.37%) The drug will get more widespread use eventually because Olinvyk is designed to stimulate the activation of the G protein pathway but not the B Arrestin pathway, meaning it should (theoretically) bring about the analgesic effects of an opioid but with the adverse effects of the latter. Peak sales of Olinvyk are forecast to be $284 million, according to H.C. Wainwright. Always do your own research and make your own investment decisions. Previously, H.C. Wainwright analyst Douglas Tsao also raised his price target to $5 on the Olinvyk news. In 2016, shares were trading over $12. In this article, we take a hard look and issue a new Trevena stock forecast. Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions. This article is not a solicitation or recommendation to buy, sell, or hold securities. For the next year, analysts forecast that the firm will report earnings of ($0.30) per share, with EPS estimates ranging from ($0.32) to ($0.27). View TRVN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. See Trevena, Inc. (TRVN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Sign up Click here now. TRV027 is already enrolled in a proof-of-concept study in COVID-19 patients at Imperial College London. In early August, the FDA approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid. The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 6.77 million shares valued at $20.23 million. Insider Financial focuses solely on short-term high probability trade opportunities. What this means: Trevena Inc (TRVN) gets an Overall Rank of 51, which is an above average rank under InvestorsObserver's stock ranking system. The stock should be watched closely. TRVN registered 149.36% gain for a year compared to 6-month gain of 39.87%. Our alerts consist of Nasdaq, NYSE and high quality OTC companies that are capable of delivering outsized gains to you today, not a year from now. Trevena (NASDAQ: TRVN) is owned by 17.41% institutional shareholders, 14.21% Trevena insiders, and 68.38% retail investors. However, with a daily trading volume of 3.45 million and changing 0.00% at the moment leaves the stock 16.11% off its SMA200. ET by Tomi Kilgore Trevena started at outperform with $16 stock price target at FBR & Co. 4 of the analysts rate the stock as a “Buy”. With the opioid crisis in America, getting a new opioid approved is next to impossible. Initial adoption to take place amongst high-risk patients. for our next MicroCap Runner ahead of the crowd! Get the hottest stocks to trade every day before the market opens 100% free. Find the latest Trevena, Inc. (TRVN) stock quote, history, news and other vital information to help you with your stock trading and investing. If this proves to be the case, it could be a real game-changer in a sector that desperately needs an overhaul. The Trevena Inc. (TRVN) shares are trading at lower $2.23 and the avg recommendation for the stock is Moderate Buy. We have no business relationship with any company whose stock is mentioned in this article. Trevena Stock Forecast. We wrote this article ourselves and it expresses our own opinions. Trevena started at buy with $15 stock price target at Ladenburg Thalmann Feb. 2, 2017 at 7:40 a.m. Trevena, Inc. (TRVN) projections and forecasts How much more room can Trevena stock run? Some negative signals were issued as well, and these may have some influence on the near short-term development. Find real-time TRVN - Trevena Inc stock quotes, company profile, news and forecasts from CNN Business. Price Target Insider Financial is not an investment advisor and does not provide investment advice. There’s even more room to run if Trevena makes progress with either one of its four other candidates: TRV250, TRV734, TRV027, and TRV045. We use big data and artificial intelligence to forecast the stock price of Trevena Inc - TRVN. Over the last 52 weeks, TRVN is down -6.69% while the S&P 500 is down … Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. 4 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. As of Sep 29, 2020, the second largest holder is NEA Management Company, LLC with 3.81 million shares valued at $11.4 million to account for 2.43% of the shares outstanding. Trevena Inc. (TRVN) has around 24 employees, a market worth around $336.00M and $3.00M in sales. TRVN Stock Trend. First up, here’s a little background if this is your first Trevena stock forecast. Dilution is no longer a concern. It’s been pretty much dead money until this summer when shares finally broke out. We hate That would give Trevena a share price of $7.85. Cantor Fitzgerald just came out and issued a $5 price target in its recent Trevena stock forecast. The stock is moving within a very wide and horizontal trend and further … The firm has a 50-day simple moving average (SMA 50) of $2.3347 and a 200-day simple moving average (SMA200) of $2.2736. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing. We cover the US equity market. Get the latest Trevena, Inc. TRVN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. As of 2021 February 25, Thursday current price of … Institutions hold 11.65% of the Float. The last time we did a Trevena stock forecast was in October of 2017, which you can read here. TRVN updated stock price target summary. Unsubscribe Anytime. For Olinvyk to be approved is a huge milestone and a major win for Trevena. The shares outstanding are 157.03M, and float is at 155.51M with Short Float at 14.78%. The stock witnessed a -9.70% loss in the last 1 month and extending the period to 3 months gives it a -27.70%, and is -13.01% down over the last 5 days. Trevena will launch Olinvyk in Q4 and we anticipate the approval will act as a catalyst for several of Trevena’s ex-US partners to provide critical non-dilutive capital in the form of milestone payments. With over 10% of the float short, the shorts are going to be forced to cover as their bear thesis has been destroyed now that Olinvyk is approved. (adsbygoogle=window.adsbygoogle||[]).push({}); We do not sell or share your information with anyone. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.18% over the week and 5.63% over the month. View Trevena, Inc. TRVN investment & stock information. The TRVN stock was last observed hovering at around $2.14 in the last trading session, with the day’s loss setting it 0.0% off its average median price target of $5.00 for the next 12 months. Of note, this particular medication is only indicated for use in a controlled clinical setting, meaning under medical supervision and not for use in a take-home prescription.”. For over five years, we have provided a free service to a countless number of traders featuring only the best in the microcap arena. We are not receiving compensation for it. The stock's open price was 2.28. Trevena has a current market cap of $296 million. Disclosure: We have no position in NASDAQ:TRVN or any of the securities mentioned. S&P 500 3,876.50 (-0.77%) DOW 31,521.69 (+0.09%)